Abivax SA Sponsored ADR (NASDAQ:ABVX) Short Interest Down 13.2% in February

Abivax SA Sponsored ADR (NASDAQ:ABVX) was the target of a significant decline in short interest in February. As of February 13th, there was short interest totaling 3,172,758 shares, a decline of 13.2% from the January 29th total of 3,656,705 shares. Based on an average daily trading volume, of 677,411 shares, the days-to-cover ratio is presently 4.7 days. Currently, 4.0% of the company’s stock are sold short. Currently, 4.0% of the company’s stock are sold short. Based on an average daily trading volume, of 677,411 shares, the days-to-cover ratio is presently 4.7 days.

Hedge Funds Weigh In On Abivax

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. UBS Group AG lifted its stake in shares of Abivax by 2,561.0% in the third quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock worth $378,761,000 after buying an additional 4,293,606 shares during the last quarter. Darwin Global Management Ltd. bought a new position in Abivax in the 3rd quarter worth $263,698,000. Morgan Stanley lifted its position in Abivax by 114.3% during the 4th quarter. Morgan Stanley now owns 3,151,994 shares of the company’s stock worth $425,062,000 after acquiring an additional 1,681,277 shares during the last quarter. Paradigm Biocapital Advisors LP acquired a new position in Abivax during the 3rd quarter worth $132,800,000. Finally, TCG Crossover Management LLC boosted its holdings in Abivax by 17.4% during the third quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock valued at $603,774,000 after acquiring an additional 1,055,000 shares during the period. Institutional investors and hedge funds own 47.91% of the company’s stock.

Analyst Ratings Changes

ABVX has been the subject of a number of research reports. Wall Street Zen lowered Abivax from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Wolfe Research upgraded shares of Abivax to a “strong-buy” rating in a report on Thursday, November 6th. Citizens Jmp upped their price objective on shares of Abivax from $114.00 to $131.00 and gave the company a “market outperform” rating in a research note on Tuesday, December 16th. Guggenheim reissued a “buy” rating and set a $175.00 target price on shares of Abivax in a research note on Thursday, December 18th. Finally, Piper Sandler restated an “overweight” rating and set a $142.00 price target on shares of Abivax in a report on Tuesday, December 16th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $134.75.

Abivax Trading Down 1.8%

Abivax stock opened at $111.10 on Wednesday. Abivax has a one year low of $4.77 and a one year high of $148.83. The company’s fifty day moving average price is $123.24 and its two-hundred day moving average price is $106.92. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.86 and a quick ratio of 7.86. The company has a market capitalization of $8.78 billion, a price-to-earnings ratio of -26.58 and a beta of 1.00.

Abivax (NASDAQ:ABVX) last released its quarterly earnings results on Monday, December 15th. The company reported ($2.46) earnings per share (EPS) for the quarter. The firm had revenue of ($4.92) million during the quarter. On average, analysts forecast that Abivax will post -2.83 earnings per share for the current fiscal year.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.